Tri

New Advances in Gastric Diagnostics: Smaller is Better

In recent years, miniaturization has opened up exciting possibilities in the area of gastric diagnostics. New technology may make routine GI diagnostic procedures as simple as swallowing a vitamin pill-sized encapsulated unit in the not-too-far future, and the present reality is that these units are becoming valuable adjuncts to traditional diagnostics. Capsule endoscopy (enteroscopy...

Bench-Top Centrifuges--Basic Tools for the Small Lab

No matter how elementary or advanced, every clinical laboratory possesses one essential devicea centrifuge. It may be a bench-top or floor model, refrigerated or non-cooled, but this apparatus, because of its unique ability to fractionate liquid specimens by creating spin-induced high g-forces, has long been a standard tool for both diagnosis and research applications. For all this utility, t...

Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

LONDON, 12 July 2007 - Cancer drug developer Antisoma plc(LSE: ASM, US OTC: ATSMY) today announces new data from its phaseII trial of ASA404 in recurrent, platinum-sensitive ovarian cancer.This trial compares patients receiving ASA404 plus chemotherapy(n=37) with patients receiving chemotherapy alone (n=38). The mainfindings are as follows: * There was no advantage in median time t...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced results of secondary endpoint data from its 99patient, randomized, placebo-controlled, multi-center Phase IIbtrial (DLXLEF-AP4) with...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.(Nasdaq:AVII) announced today that its partner Cook Medical hascompleted target patient enrollment and released six-monthfollow-up data from a Phase II clinical trial known as Appraisal.The trial, currently being held in Germany, was designed to studythe effect of the Neugene(R) antisense drug Resten-MP(TM), whenused in conj...

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX NewsNetwork) -- Generex Biotechnology Corporation (Nasdaq:GNBT), theleader in drug delivery for metabolic diseases through the innerlining of the mouth, announced today that it will be making threeposter presentations at the 46th Annual Meeting of the EuropeanSociety of Pediatric Endocrinology in Helsinki, Finland June 27 --30, 200...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa ClinicalTrial Results First clinical Results Confirm Potential New Application of KeyProduct in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced the positiveclinical results of its...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a company "Advancing Drugs ThroughGlycoscience(R)", today updated the progress of its Phase IIclinical trial for first-line treatment of metastatic, unresectablecolorectal cancer patients who are unable to tolerate irinotecanand/or oxaliplatin, and its Phase II clinical trial for first-linetreatment of bilia...

MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

MARTINSRIED/MUNICH, Germany, July 9, 2007-A virus that has beenspecifically designed by scientists to be safe to normal tissue butdeadly to cancer is showing early promise in a preliminary study,researchers said today at the ESMO Conference Lugano (ECLU),Switzerland. The virus, called NV1020, is a type of herpes simplex virusmodified so that it selectively replicates in virus cells...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...

Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australianbiotechnology company Avexa (ASX:AVX) announced today thecompletion of apricitabine's controlled, double blinded phase whichrepresents the first 24 week segment of its Phase IIb trial.Patients have now progressed into the open-label section of thetrial (weeks 24 to 48) and will continue to receive 800mgapricitabine twice a day a...

Genzyme Announces Results of Clinical Trial of Hylastan

CAMBRIDGE, Mass., July 05, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. today announced top-line results from a pivotal studyinvestigating the safety and efficacy of hylastan in treating painin patients with osteoarthritis (OA) of the knee. Hylastan is beingdeveloped within Genzyme's program to introduce aviscosupplementation product that can be delivered through a singleknee injection. T...

From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials

PHILADELPHIA, July 3, 2007-- Ongoing therapeutic cancer vaccinetrials have yet to show evidence of vaccines spurring apatient’s immune system to shrink tumors -- yet patients whoreceive these vaccines in trials tend to live longer and respondbetter to subsequent treatment. In the July 1 issue of ClinicalCancer Research, a journal of the American Association for CancerResearch, a te...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

ENDEAVOR IV Clinical Trial Meets Primary Endpoint

MINNEAPOLIS--(BUSINESS WIRE)--Jul 2, 2007 - Medtronic, Inc.,(NYSE:MDT) today announced that a review of data from the ENDEAVORIV Clinical Trial indicates that the trial has met its primary,non-inferiority endpoint. The ENDEAVOR IV Clinical Trial is a randomized, single-blindtrial evaluating the safety and efficacy of the Endeavor(TM) DrugEluting Coronary Stent as compared to the TAXUS Pac...

Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial

Provides Update to Timeline for Second Pivotal Phase 3 Trial CL-05 CHICAGO, July 02, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced the confirmation ofsupplemental efficacy data from Trial CL-06, the first of twopivotal Phase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatme...

Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced that it will host aconference call and live webcast at 10:00 am (EDT) on Monday, July2, 2007 to discuss data from Trial CL-06, the first of two pivotalPhase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatment...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics,Incorporated (Nasdaq: CYTK) announced results from the analyses ofthree Phase II clinical trials of ispinesib administered asmonotherapy, one in patients with hepatocellular cancer, one inpatients with melanoma, and one in patients with hormone-refractoryprostate cancer. I...

European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGene's Cancer-Killing Virus in Press Conference

* Presentation of efficacy trends from ongoing phase I/II trialof oncolytic HSV * Poster selected by ESMO for presentation inpress conference MARTINSRIED, Germany, June 29, 2007.--The biotech companyMediGene AG (Frankfurt, Prime Standard: MDG) announces that a casereport from the ongoing clinical trial of MediGene's cancer killingvirus will be presented in a press conferen...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis

TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday,June 27 at the Jefferies Healthcare Conference that its interimanalysis of the blinded data on the first fifty patients in theFast-Tracked Phase 3 clinical study of SinuNase(TM), at 8 weekspost-randomization, has demonstrated substantial improvement inresolution of one or both...

Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profilingin Diabetic Patients BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel(SWX: SPPN) today announced that it has reached another significantmilestone in the development of its family of renin inhibitors withthe successful completion of a Phase IIa proof-of-concept clinicaltrial with SPP635 for the treat...

Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study

SYDNEY, Australia--(BUSINESS WIRE)--Jun 27, 2007 - PrimeCell(TM)Therapeutics LLC (http://www.primecelltherapeutics.com) todayannounced that it provided research support and pre-clinicalstudies for a clinical trial to assess the safety, feasibility andefficacy of implanting autologous bone marrow stem cells intospinal cord injury (SCI) patients. Dr. Luis Geffner presented a preliminary rep...

Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells

SAN DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The University ofPittsburgh School of Health Sciences issued the following study andpress release, "Scientists Culture Blood-Forming Stem Cells fromHuman Fat Tissue," June 15, 2007, Science Daily: "Researchers atthe University of Pittsburgh School of Medicine have successfullyisolated and cultured human hematopoietic stem cells from fat, oradipose...

Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target

OSS, the Netherlands, June 27, 2007-Organon, the humanhealthcare business unit of Akzo Nobel, announced today that twoout of three Phase III clinical trials with corifollitropin alfa(Org 36286), a new long-acting fertility hormone, have reachedtheir randomization target. Corifollitropin alfa is a new recombinant fertility hormone. It isthe first of a new class of gonadotropi...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayannounced promising data from the six-month, open-label extensionof its completed Phase IIa clinical trial with arimoclomol in ALSvolunteers. While the clinical trial was not placebo-controlled,arimoclomol at a 1...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, anemerging pharmaceutical company specialized in ophthalmologypresents positive results of its pivotal phase III clinical trialpositive results from the Phase III clinical study of Vekacia(R) inchildren suffering from Vernal Keratoconjunctivitis (VKC) at theXIV Afro-Asian Congress of ophthalmology (AACO) held from June 20to 25...

Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhoodcancers are fortunately rare, but among them, neuroblastoma is aspecial case, accounting for 7 percent of all childhood cancers,but 15 percent of childhood cancer deaths. It typically occurs as asolid tumor in the abdomen, but also in the neck, chest, andpelvis, developing in the network of the body's sympathetic nervoussyst...

CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayreported safety and tolerability results from its previouslyannounced double-blind, placebo-controlled, rising multiple doseclinical trial in healthy volunteers with its drug candidatearimoclomol. CytRx believes...

Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 25, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced positive top-lineresults from two dose-ranging, Phase 2b clinical trials in chronicinsomnia patients with the Company's proprietary insomnia agent,NG2-73, an alpha-3 preferring GABA(A) partial agonist. Multipleformulations were studied in each trial to determine the bestprofile for rapidity o...